MX2016004282A - Variantes de protoxina-ii y metodos de uso. - Google Patents

Variantes de protoxina-ii y metodos de uso.

Info

Publication number
MX2016004282A
MX2016004282A MX2016004282A MX2016004282A MX2016004282A MX 2016004282 A MX2016004282 A MX 2016004282A MX 2016004282 A MX2016004282 A MX 2016004282A MX 2016004282 A MX2016004282 A MX 2016004282A MX 2016004282 A MX2016004282 A MX 2016004282A
Authority
MX
Mexico
Prior art keywords
protoxin
variants
methods
foregoing
making
Prior art date
Application number
MX2016004282A
Other languages
English (en)
Inventor
Robert Neff
Yi Liu
Alan Wickenden
Flinspach Mack
Fellows Ross
Hagan Rebecca
Xu Qinghao
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2016004282A publication Critical patent/MX2016004282A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Insects & Arthropods (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a variantes de Protoxina-Il, polinucleótidos que los codifican, y métodos para hacer y usar lo anterior.
MX2016004282A 2013-10-03 2014-10-03 Variantes de protoxina-ii y metodos de uso. MX2016004282A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361886100P 2013-10-03 2013-10-03
PCT/US2014/058972 WO2015051216A1 (en) 2013-10-03 2014-10-03 Protoxin-ii variants and methods of use

Publications (1)

Publication Number Publication Date
MX2016004282A true MX2016004282A (es) 2016-10-12

Family

ID=51830620

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016004282A MX2016004282A (es) 2013-10-03 2014-10-03 Variantes de protoxina-ii y metodos de uso.

Country Status (12)

Country Link
US (2) US9624280B2 (es)
EP (2) EP3825323A1 (es)
JP (3) JP6676523B2 (es)
KR (1) KR20160064192A (es)
CN (1) CN105793277B (es)
AU (1) AU2014329454B2 (es)
BR (1) BR112016007062A2 (es)
CA (1) CA2926052A1 (es)
ES (1) ES2841173T3 (es)
MX (1) MX2016004282A (es)
PH (1) PH12016500598A1 (es)
WO (1) WO2015051216A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10414808B2 (en) 2012-05-18 2019-09-17 Janssen Biotech, Inc. Huwentoxin-IV variants and methods of use
ES2841173T3 (es) 2013-10-03 2021-07-07 Janssen Biotech Inc Variantes de Protoxina-II y métodos de uso
MA41642A (fr) 2015-03-03 2018-01-09 Janssen Biotech Inc Variants de protoxine ii et méthodes d'utilisation
JP6985151B2 (ja) 2015-04-02 2021-12-22 ヤンセン バイオテツク，インコーポレーテツド プロトキシン−ｉｉ変異体及びその使用方法
US11801313B2 (en) 2016-07-06 2023-10-31 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of pain related disorders
CN109843914B (zh) 2016-07-06 2024-03-15 沃泰克斯药物股份有限公司 用于治疗疼痛相关病症的材料和方法
EP3568411B1 (en) * 2017-01-13 2024-03-06 Pietro P. Sanna Methods and compositions for treating hpa hyperactivity
JP2024505570A (ja) * 2021-02-01 2024-02-06 ナヴェガ セラピューティクス， インコーポレイテッド 神経学的疾患及び疼痛を治療するためのエピジェネティック遺伝子調節
WO2024011119A2 (en) * 2022-07-06 2024-01-11 The Regents Of The University Of California Peptides targeting sodium channels to treat pain
CN120699106A (zh) * 2024-03-26 2025-09-26 广州锡滔生物医药科技有限公司 一种多肽及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309989A (en) 1976-02-09 1982-01-12 The Curators Of The University Of Missouri Topical application of medication by ultrasound with coupling agent
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
EP1005526B1 (en) 1997-04-16 2010-10-13 Unigene Laboratories, Inc. Direct expression of peptides into culture media
IL120943A (en) 1997-05-29 2004-03-28 Univ Ben Gurion A system for administering drugs through the skin
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
DK1015576T3 (da) 1997-09-16 2005-08-29 Egea Biosciences Llc Fremgangsmåde til fuldstændig kemisk syntese og aggregering af gener og genomer
US20030148273A1 (en) 2000-08-26 2003-08-07 Shoulian Dong Target enrichment and amplification
EP1348466A3 (en) 2002-02-01 2003-10-29 Inspire Pharmaceuticals, Inc. Method for treating pain with adenosine-tetraphosphates
US7659082B2 (en) 2002-02-19 2010-02-09 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
JP4929288B2 (ja) 2005-11-04 2012-05-09 アルナイラム ファーマシューティカルズ， インコーポレイテッド Ｎａｖ１．８遺伝子の発現を抑制するための組成物および方法
WO2007109324A2 (en) 2006-03-21 2007-09-27 Xenon Pharmaceuticals, Inc. Potent and selective nav 1.7 sodium channel blockers
BRPI0716228A2 (pt) 2006-09-08 2013-10-15 Mayo Foundation Polipeptídeos aquaréticos e natriuréticos carecendo de atividade vasodilatadora
US7998980B2 (en) 2006-09-15 2011-08-16 Hydra Biosciences, Inc. Compounds for modulating TRPV3 function
PE20081140A1 (es) 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
EP2334315B1 (en) 2008-09-03 2023-01-18 NoNO Inc. Agents and methods for treatment of pain
WO2010104115A1 (ja) 2009-03-10 2010-09-16 独立行政法人産業技術総合研究所 膜タンパク質を特異的に認識するポリペプチドの調製方法
CA2774350A1 (en) 2009-09-15 2011-03-24 Alomone Preclinical Ltd. Novel peptides isolated from spider venom, and uses thereof
ES2665500T3 (es) 2010-03-08 2018-04-26 Dana-Farber Cancer Institute, Inc. Enriquecimiento de una PCR por COLD completa con secuencia de bloqueo de referencia
WO2012004664A2 (en) * 2010-07-07 2012-01-12 Purdue Pharma L.P. Analogs of sodium channel peptide toxin
CN101979411A (zh) 2010-10-21 2011-02-23 湖南师范大学 虎纹捕鸟蛛蛋白酶抑制剂
CN103492575A (zh) 2011-01-18 2014-01-01 安姆根有限公司 NaV1.7敲除小鼠及其用途
EP3382039B1 (en) 2011-05-04 2023-09-13 Biocept, Inc. Methods for detecting nucleic acid sequence variants
US10414808B2 (en) 2012-05-18 2019-09-17 Janssen Biotech, Inc. Huwentoxin-IV variants and methods of use
US9102751B2 (en) 2012-05-18 2015-08-11 Janssen Biotech, Inc. Huwentoxin-IV variants and methods of use
CA2873860A1 (en) 2012-05-18 2013-11-21 Janssen Biotech, Inc. Huwentoxin-iv variants and methods of use
WO2014016673A1 (en) 2012-07-27 2014-01-30 Purdue Pharma L.P. Sodium channel blocking peptides and the use thereof
US10344060B2 (en) 2013-03-12 2019-07-09 Amgen Inc. Potent and selective inhibitors of Nav1.7
CN104065367B (zh) 2013-03-20 2017-11-07 江苏多维科技有限公司 一种低功耗磁电阻开关传感器
ES2841173T3 (es) 2013-10-03 2021-07-07 Janssen Biotech Inc Variantes de Protoxina-II y métodos de uso
MA41642A (fr) 2015-03-03 2018-01-09 Janssen Biotech Inc Variants de protoxine ii et méthodes d'utilisation
JP6985151B2 (ja) 2015-04-02 2021-12-22 ヤンセン バイオテツク，インコーポレーテツド プロトキシン−ｉｉ変異体及びその使用方法

Also Published As

Publication number Publication date
WO2015051216A1 (en) 2015-04-09
ES2841173T3 (es) 2021-07-07
JP6676523B2 (ja) 2020-04-08
JP2020096606A (ja) 2020-06-25
JP2022008319A (ja) 2022-01-13
HK1224307A1 (zh) 2017-08-18
EP3052519B1 (en) 2020-11-25
AU2014329454A1 (en) 2016-04-21
EP3825323A1 (en) 2021-05-26
CN105793277A (zh) 2016-07-20
JP2016533710A (ja) 2016-11-04
KR20160064192A (ko) 2016-06-07
US20150099705A1 (en) 2015-04-09
CN105793277B (zh) 2020-09-15
US9624280B2 (en) 2017-04-18
PH12016500598A1 (en) 2016-06-13
US10975129B2 (en) 2021-04-13
BR112016007062A2 (pt) 2017-09-12
EP3052519A1 (en) 2016-08-10
AU2014329454B2 (en) 2019-01-17
US20200048316A1 (en) 2020-02-13
CA2926052A1 (en) 2015-04-09
JP6940636B2 (ja) 2021-09-29

Similar Documents

Publication Publication Date Title
PH12018501839A1 (en) St2l antagonists and methods of use
PH12016500598A1 (en) Protoxin-ii variants and methods of use
PH12016501763A1 (en) Multispecific antibodies
SG10201811017QA (en) Novel antibody frameworks
PH12015501627B1 (en) Kv1.3 antagonists and methods of use
MX2017011223A (es) Variantes de protoxina ii y metodos de uso.
MX2017012654A (es) Variantes de protoxina-ii y metodos de uso.
PH12016500826A1 (en) Anti-ccl17 antibodies
MX362070B (es) Polioles que contienen tanino, su producción y su uso.
IL240412A0 (en) Corrupt carrier coding
IN2014DN09798A (es)
IN2013MU03768A (es)
MX2015009161A (es) Polioles, su preparación y su uso.
MY184721A (en) Use of odiparcil in the treatment of a mucopolysaccharidosis
AU353233S (en) Novelty Pen
IN2013CH00453A (es)
UA80618U (en) Use of n-steroylethanolamine as radiomodifier
AU350093S (en) Compact
AU352571S (en) Dress